Iovance Biotherapeutics, Inc. (IOVA)
Automate Your Wheel Strategy on IOVA
With Tiblio's Option Bot, you can configure your own wheel strategy including IOVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IOVA
- Rev/Share 0.6587
- Book/Share 2.3783
- PB 0.8746
- Debt/Equity 0.07
- CurrentRatio 4.1783
- ROIC -0.4632
- MktCap 694582720.0
- FreeCF/Share -1.0763
- PFCF -1.9988
- PE -1.7891
- Debt/Assets 0.0556
- DivYield 0
- ROE -0.4971
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IOVA | UBS | Buy | Neutral | -- | $2 | May 16, 2025 |
| Downgrade | IOVA | Truist | Buy | Hold | -- | -- | May 12, 2025 |
| Downgrade | IOVA | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | May 9, 2025 |
News
ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.
Read More
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
Published: June 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 17, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153457&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
Read More
IOVA SHAREHOLDER ALERT: BFA Law Reminds Iovance Biotherapeutics, Inc. Investors of Upcoming July 14 Class Action Deadline - Contact the Firm if You Suffered Losses
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before July 14, 2025
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153351&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153343&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Join Class Action to Recover Losses from Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153333&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq.
Read More
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 16, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
Read More
Investors in Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights - Contact Levi & Korsinsky Before July 14, 2025
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153303&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.
Read More
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
Read More
Class Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA) - Join by July 14, 2025 - Contact Levi & Korsinsky
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153262&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.
Read More
IOVA CLASS ACTION NOTICE: Iovance Biotherapeutics, Inc. Was Sued For Securities Fraud; Contact BFA Law if You Suffered Losses
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Class Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA) - Join by July 14, 2025 - Contact Levi & Korsinsky
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153045&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.
Read More
Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact Levi & Korsinsky about pending Class Action - IOVA
Published: June 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.
Read More
Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: June 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, June 13, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”).
Read More
July 14, 2025 Deadline Approaching: Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153040&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq.
Read More
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
Published: June 13, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"), of the important July 14, 2025 lead plaintiff deadline. So What: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Join Class Action to Recover Losses from Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153033&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky to Join Class Action Before July 14, 2025
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=152994&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.
Read More
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
Published: June 13, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 13, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
Read More
Shareholders of Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights Before July 14, 2025 - Contact Levi & Korsinsky
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=152984&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.
Read More
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: June 13, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 13, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
Read More
IOVA CLASS ACTION ALERT: Iovance Biotherapeutics, Inc. Investors With Losses Are Notified to Contact BFA Law About The Securities Fraud Class Action Lawsuit
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Iovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 14, 2025 to Discuss Your Rights – IOVA
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).
Read More
Shareholders of Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights Before July 14, 2025 - Contact Levi & Korsinsky
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=152824&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.
Read More
Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit - Hagens Berman
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
IOVA Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / June 12, 2025 / A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: June 12, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 12, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). IF YOU SUFFERED A LOSS ON YOUR IOVANCE INVESTMENTS, CLICK HERE BEFORE JULY 14, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
July 14, 2025 Deadline: Join Class Action Lawsuit Against Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=152671&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.
Read More
Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 11, 2025 (GLOBE NEWSWIRE) -- A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically. On May 16, 2025, UBS analysts reportedly slashed their rating on Iovance shares from Buy to Neutral and issued a stark price target cut—from $17 to just $2—citing mounting concerns over the drug's commercial rollout and the company's ability to meet market expectations. The analyst downgrade comes as Iovance faces additional scrutiny in the form of securities class action litigation filed …
Read More
About Iovance Biotherapeutics, Inc. (IOVA)
- IPO Date 2010-10-15
- Website https://www.iovance.com
- Industry Biotechnology
- CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D.
- Employees 838